Skip to content
Middletown Life
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Tech
Travel
Author:
Crystalys Therapeutics / Russo Partners
Crystalys Therapeutics Announces $130 Million Series B Financing to Advance Global Phase 3 Development and Commercialization of Dotinurad for Gout
July 22, 2026
Crystalys Therapeutics Doses First Patients in New Phase 2 Trial of Dotinurad for Difficult-to-Treat Gout
May 26, 2026
Crystalys Therapeutics Expands Phase 3 RUBY Study With First Patients Dosed at European Sites
February 11, 2026